Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

2.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
3.

Inhibiting system xC- and glutathione biosynthesis - a potential Achilles' heel in mutant-p53 cancers.

Clemons NJ, Liu DS, Duong CP, Phillips WA.

Mol Cell Oncol. 2017 Jul 5;4(5):e1344757. doi: 10.1080/23723556.2017.1344757. eCollection 2017.

4.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

5.

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Jacquelot N, Pitt JM, Enot DP, Roberti MP, Duong CPM, Rusakiewicz S, Eggermont AM, Zitvogel L.

Oncoimmunology. 2017 Mar 7;6(8):e1299303. doi: 10.1080/2162402X.2017.1299303. eCollection 2017. Review.

6.

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ.

Nat Commun. 2017 Mar 28;8:14844. doi: 10.1038/ncomms14844.

7.

Preclinical models of esophageal adenocarcinoma for drug development.

Liu DS, Duong CP, Phillips WA, Clemons NJ.

Discov Med. 2016 Dec;22(123):371-379. Review.

8.

Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis.

Liu DS, Hoefnagel SJ, Fisher OM, Krishnadath KK, Montgomery KG, Busuttil RA, Colebatch AJ, Read M, Duong CP, Phillips WA, Clemons NJ.

Oncotarget. 2016 Dec 13;7(50):83342-83358. doi: 10.18632/oncotarget.13391.

9.

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, Routy B, Jacquelot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L.

Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.

10.

The Genetics of Barrett's Esophagus: A Familial and Population-Based Perspective.

To H, Clemons NJ, Duong CP, Trainer AH, Phillips WA.

Dig Dis Sci. 2016 Jul;61(7):1826-34. doi: 10.1007/s10620-016-4109-2. Epub 2016 Mar 12. Review.

PMID:
26971090
11.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

12.

Incremental diagnostic utility of gastric distension FDG PET/CT.

Le Roux PY, Duong CP, Cabalag CS, Parameswaran BK, Callahan J, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):644-53. doi: 10.1007/s00259-015-3211-6. Epub 2015 Oct 21.

PMID:
26487512
13.

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.

Liu DS, Read M, Cullinane C, Azar WJ, Fennell CM, Montgomery KG, Haupt S, Haupt Y, Wiman KG, Duong CP, Clemons NJ, Phillips WA.

Gut. 2015 Oct;64(10):1506-16. doi: 10.1136/gutjnl-2015-309770. Epub 2015 Jul 17.

PMID:
26187504
14.

Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Devaud C, Westwood JA, Teng MW, John LB, Yong CS, Duong CP, Smyth MJ, Darcy PK, Kershaw MH.

Oncoimmunology. 2014 Dec 21;3(11):e963395. eCollection 2014 Nov.

15.

Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts.

Read M, Liu D, Duong CP, Cullinane C, Murray WK, Fennell CM, Shortt J, Westerman D, Burton P, Clemons NJ, Phillips WA.

Ann Surg Oncol. 2016 Jan;23(1):305-11. doi: 10.1245/s10434-015-4425-3. Epub 2015 Feb 18.

PMID:
25691278
16.

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.

Duong CP, Yong CS, Kershaw MH, Slaney CY, Darcy PK.

Mol Immunol. 2015 Oct;67(2 Pt A):46-57. doi: 10.1016/j.molimm.2014.12.009. Epub 2015 Jan 13. Review.

PMID:
25595028
17.

Foxp3 expression in macrophages associated with RENCA tumors in mice.

Devaud C, Yong CS, John LB, Westwood JA, Duong CP, House CM, Denoyer D, Li J, Darcy PK, Kershaw MH.

PLoS One. 2014 Sep 29;9(9):e108670. doi: 10.1371/journal.pone.0108670. eCollection 2014.

18.

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.

Westwood JA, Matthews GM, Shortt J, Faulkner D, Pegram HJ, Duong CP, Chesi M, Bergsagel PL, Sharp LL, Huhn RD, Darcy PK, Johnstone RW, Kershaw MH.

Leuk Res. 2014 Aug;38(8):948-54. doi: 10.1016/j.leukres.2014.05.010. Epub 2014 Jun 2.

PMID:
24934848
19.

A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology.

Cabalag CS, Chan ST, Kaneko Y, Duong CP.

Gastric Cancer. 2015 Jan;18(1):11-22. doi: 10.1007/s10120-014-0388-5. Epub 2014 Jun 3.

PMID:
24890254
20.

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ, Darcy PK, Kershaw MH.

Mol Ther. 2014 Jan;22(1):18-27. doi: 10.1038/mt.2013.219. Epub 2013 Sep 19.

21.

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK.

Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.

22.

Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer.

Tran TN, Brettingham-Moore K, Duong CP, Mitchell C, Clemons NJ, Phillips WA.

J Surg Oncol. 2013 Aug;108(2):113-20. doi: 10.1002/jso.23357. Epub 2013 Jun 28.

PMID:
23813545
23.

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.

Henderson MA, Yong CS, Duong CP, Davenport AJ, John LB, Devaud C, Neeson P, Westwood JA, Darcy PK, Kershaw MH.

Immunotherapy. 2013 Jun;5(6):577-90. doi: 10.2217/imt.13.37.

PMID:
23725282
24.

Engineering T cell function using chimeric antigen receptors identified using a DNA library approach.

Duong CP, Westwood JA, Yong CS, Murphy A, Devaud C, John LB, Darcy PK, Kershaw MH.

PLoS One. 2013 May 7;8(5):e63037. doi: 10.1371/journal.pone.0063037. Print 2013.

25.

Laparoscopy and peritoneal cytology: important prognostic tools to guide treatment selection in gastric adenocarcinoma.

Tourani SS, Cabalag C, Link E, Chan ST, Duong CP.

ANZ J Surg. 2015 Jan;85(1-2):69-73. doi: 10.1111/ans.12197. Epub 2013 May 6.

PMID:
23647832
26.

18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.

Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ.

J Nucl Med. 2012 Jun;53(6):864-71. doi: 10.2967/jnumed.111.101568. Epub 2012 May 11.

27.

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.

John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2012 Apr 1;72(7):1651-60. doi: 10.1158/0008-5472.CAN-11-2788. Epub 2012 Feb 7.

28.

Autoimmunity associated with immunotherapy of cancer.

Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH.

Blood. 2011 Jul 21;118(3):499-509. doi: 10.1182/blood-2011-01-325266. Epub 2011 Apr 29. Review. Erratum in: Blood. 2012 Dec 20;120(26):5251.

29.

Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma.

Brettingham-Moore KH, Duong CP, Greenawalt DM, Heriot AG, Ellul J, Dow CA, Murray WK, Hicks RJ, Tjandra J, Chao M, Bui A, Joon DL, Thomas RJ, Phillips WA.

Clin Cancer Res. 2011 May 1;17(9):3039-47. doi: 10.1158/1078-0432.CCR-10-2915. Epub 2011 Jan 11.

30.

Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.

Duong CP, Westwood JA, Berry LJ, Darcy PK, Kershaw MH.

Immunotherapy. 2011 Jan;3(1):33-48. doi: 10.2217/imt.10.81.

PMID:
21174556
31.

Using gene expression profiling to predict response and prognosis in gastrointestinal cancers-the promise and the perils.

Brettingham-Moore KH, Duong CP, Heriot AG, Thomas RJ, Phillips WA.

Ann Surg Oncol. 2011 May;18(5):1484-91. doi: 10.1245/s10434-010-1433-1. Epub 2010 Nov 23. Review.

PMID:
21104326
32.

Tumor ablation by gene-modified T cells in the absence of autoimmunity.

Wang LX, Westwood JA, Moeller M, Duong CP, Wei WZ, Malaterre J, Trapani JA, Neeson P, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2010 Dec 1;70(23):9591-8. doi: 10.1158/0008-5472.CAN-10-2884. Epub 2010 Nov 23.

33.

Enhancing adoptive immunotherapy of cancer.

Westwood JA, Berry LJ, Wang LX, Duong CP, Pegram HJ, Darcy PK, Kershaw MH.

Expert Opin Biol Ther. 2010 Apr;10(4):531-45. doi: 10.1517/14712591003610622. Review.

PMID:
20132063
34.

FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer.

Duong CP, Hicks RJ, Weih L, Drummond E, Leong T, Michael M, Thomas RJ.

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8. Epub 2006 Mar 21.

PMID:
16550384
35.

Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer.

Duong CP, Demitriou H, Weih L, Thompson A, Williams D, Thomas RJ, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):759-69. Epub 2006 Feb 10.

PMID:
16470369

Supplemental Content

Loading ...
Support Center